Freedom Biosciences Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Freedom Biosciences's estimated annual revenue is currently $697.5k per year.(i)
  • Freedom Biosciences's estimated revenue per employee is $77,500

Employee Data

  • Freedom Biosciences has 9 Employees.(i)
  • Freedom Biosciences grew their employee count by 29% last year.

Freedom Biosciences's People

NameTitleEmail/Phone
1
CEO & Co-founderReveal Email/Phone
2
Co-founder & Chief Scientific AdvisorReveal Email/Phone
3
Chief Medical OfficerReveal Email/Phone
4
Chief StaffReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$81.4M37540%N/AN/A
#2
$16.9M10922%N/AN/A
#3
$156.1M120-70%$145MN/A
#4
$2.9M37-24%$150MN/A
#5
$1.3M170%$459.5MN/A
#6
$49.2M25415%$180.7MN/A
#7
$7M45-2%N/AN/A
#8
$256.3M8409%$168.5MN/A
#9
$4.2M27-7%N/AN/A
#10
$10.1M655%N/AN/A
Add Company

What Is Freedom Biosciences?

Freedom Biosciences is a clinical-stage biotechnology platform developing next-generation psychedelic therapeutics. Through its discovery platform, Freedom Biosciences has identified the most efficacious combinations of chemicals to advance the safety and therapeutic profiles of existing psychedelic therapeutics. With programs with clinical data and multiple exploratory programs, Freedom Biosciences has a diverse portfolio of assets that are positioned to significantly change the way we treat mental health indications. Freedom Biosciences is co-founded by Dr. John Krystal and Dina Burkitbayeva. Dr. John Krystal is the Chair of the Department of Psychiatry at Yale University and Chief of Psychiatry and Behavioral Health at Yale-New Haven Hospital. Dina Burkitbayeva is a co-founder of PsyMed Ventures.

keywords:N/A

N/A

Total Funding

9

Number of Employees

$697.5k

Revenue (est)

29%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$0.7M9N/AN/A
#2
$0.7M9N/AN/A
#3
$0.7M9N/AN/A
#4
$0.7M9N/AN/A
#5
$0.7M9N/AN/A